search
Back to results

PK Study of ACHN-490 Injection in Renally Impaired Subjects

Primary Purpose

Renal Insufficiency

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
ACHN-490 Injection
Sponsored by
Achaogen, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Insufficiency focused on measuring PK study

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male and female subjects between 18 and 75 years of age and with a body mass index ≥ 19 to ≤ 32 kg/m2, and weight of ≥ 40 kg.
  2. Normal renal function (Group I), or pre-existing renal impairment (Groups II- IV). The disease process responsible for the underlying renal dysfunction must be stable at the time of study entry, and the subject cannot have had episodes of acute renal disease in the year prior to dosing.
  3. Two CrCl determinations obtained during the screening portion of the study, with the lower value within 25% of the higher value.
  4. Females of child-bearing potential (defined as less than one year post-menopause) are eligible for enrollment if they are not breast feeding, they have a negative serum pregnancy test before study entry, and they are willing to use a highly effective method of contraception* for at least three months before study drug administration, during the study, and for at least one month after study completion.
  5. Subjects in stable health as judged by the investigator based on the laboratory criteria and no clinically significant findings on the medical history or physical examination.
  6. Subjects who are willing to comply with all study activities and procedures and have provided written informed consent prior to any study procedures and have signed and dated a HIPAA authorization form.

Exclusion Criteria:

  1. Subjects requiring hemodialysis or peritoneal dialysis
  2. Unstable cardiovascular disease,
  3. Uncontrolled hypertension, asthma, diabetes (type I or type II), thyroid disease, or seizure disorder.
  4. Myasthenia gravis, or any other neuromuscular disorder.
  5. Known infection with Hepatitis B (antigen positive), Hepatitis C (antibody positive), or HIV.
  6. Active malignancy; carcinoma in situ of the prostate or the skin (basal cell or squamous cell) are permitted.
  7. Presence of functioning transplant organ or blood procedure.
  8. Significant change in either over-the-counter or prescription medications or supplements within the two weeks prior to dosing, defined as any new medication or any dosage adjustment that is significant in the judgment of the investigator and the medical monitor.
  9. Use of drugs known to cause renal disease such as non-steroidal anti-inflammatory drugs in the two weeks prior to dosing.
  10. History of significant hearing loss or a family history of hearing loss, excluding age related (≥ age 65) hearing loss. A prior diagnosis of sensorineural hearing loss or Ménière's disease.
  11. Clinically significant illness, including viral syndromes within three weeks of dosing.
  12. Current participation in a clinical study of an investigational product.
  13. Taken any investigational medication/therapy within 30 days or 5 half-lives, whichever is longer, before dosing of ACHN-490 Injection.
  14. Consumed more than 28 units of ethanol per week at any time in the 6 months before dosing (1 unit of ethanol is equivalent to 8 ounces of beer, 4 ounces of wine, or 1 ounce of spirits) or history of alcoholism and/or drug/chemical abuse. Also, consumption of any amount of ethanol within 48 hours of ACHN-490 Injection dosing.
  15. Donated more than 500 mL of blood within 60 days prior to signing the informed consent form.
  16. Previous participation in this or any other ACHN-490 Injection study.
  17. Known hypersensitivity to Aminoglycosides or any component of the ACHN-490 Injection.
  18. Any other medical, psychological, or social condition which, in the opinion of the principal investigator (PI) or the medical monitor, would prevent the subject from fully participating in the study, would represent a concern for study compliance or would constitute a safety concern to the subject.
  19. An employee of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, or a family member of the employee or investigator.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    ACHN-490 Injection

    Arm Description

    Outcomes

    Primary Outcome Measures

    Composite of Pharmacokinetics
    Plasma PK parameters, including area under the curve from time zero to the last quantifiable sample (AUC0-t) and also extrapolated to infinity (AUC0-∞) total clearance (CLT), steady-state volume of distribution (Vss), maximum concentration (Cmax), time to maximum plasma concentration (Tmax), and the terminal-phase half life (t1/2) Urine PK including renal clearance (CLR), fraction of drug excreted in the urine expressed as a percentage of the ACHN-490 dose administered (Ae%), and amount of drug excreted in the urine through 24 hours (Ae0-24) and through 48 hours (Ae0-48).

    Secondary Outcome Measures

    Safety
    Safety and tolerability, including adverse events (AEs), and incidence and magnitude of clinically significant changes from baseline in clinical laboratory values (hematology, chemistry, and urinalysis), physical examination, and electrocardiogram (ECG).

    Full Information

    First Posted
    September 9, 2011
    Last Updated
    August 21, 2012
    Sponsor
    Achaogen, Inc.
    Collaborators
    Department of Health and Human Services
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01462136
    Brief Title
    PK Study of ACHN-490 Injection in Renally Impaired Subjects
    Official Title
    A Phase 1 Study To Assess The Pharmacokinetics, Safety, And Tolerability of Intravenous ACHN-490 Injection in Volunteers With Varying Degrees of Renal Dysfunction Compared to Healthy Volunteers
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2012
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2011 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Achaogen, Inc.
    Collaborators
    Department of Health and Human Services

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purposes of this study is to assess the relationship between renal function and pharmacokinetics of ACHN-490 Injection.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Renal Insufficiency
    Keywords
    PK study

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    24 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    ACHN-490 Injection
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    ACHN-490 Injection
    Intervention Description
    7.5 mg/kg single dose administered intravenously over 30 minutes
    Primary Outcome Measure Information:
    Title
    Composite of Pharmacokinetics
    Description
    Plasma PK parameters, including area under the curve from time zero to the last quantifiable sample (AUC0-t) and also extrapolated to infinity (AUC0-∞) total clearance (CLT), steady-state volume of distribution (Vss), maximum concentration (Cmax), time to maximum plasma concentration (Tmax), and the terminal-phase half life (t1/2) Urine PK including renal clearance (CLR), fraction of drug excreted in the urine expressed as a percentage of the ACHN-490 dose administered (Ae%), and amount of drug excreted in the urine through 24 hours (Ae0-24) and through 48 hours (Ae0-48).
    Time Frame
    0-96 hours
    Secondary Outcome Measure Information:
    Title
    Safety
    Description
    Safety and tolerability, including adverse events (AEs), and incidence and magnitude of clinically significant changes from baseline in clinical laboratory values (hematology, chemistry, and urinalysis), physical examination, and electrocardiogram (ECG).
    Time Frame
    Days 1 to 14

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Male and female subjects between 18 and 75 years of age and with a body mass index ≥ 19 to ≤ 32 kg/m2, and weight of ≥ 40 kg. Normal renal function (Group I), or pre-existing renal impairment (Groups II- IV). The disease process responsible for the underlying renal dysfunction must be stable at the time of study entry, and the subject cannot have had episodes of acute renal disease in the year prior to dosing. Two CrCl determinations obtained during the screening portion of the study, with the lower value within 25% of the higher value. Females of child-bearing potential (defined as less than one year post-menopause) are eligible for enrollment if they are not breast feeding, they have a negative serum pregnancy test before study entry, and they are willing to use a highly effective method of contraception* for at least three months before study drug administration, during the study, and for at least one month after study completion. Subjects in stable health as judged by the investigator based on the laboratory criteria and no clinically significant findings on the medical history or physical examination. Subjects who are willing to comply with all study activities and procedures and have provided written informed consent prior to any study procedures and have signed and dated a HIPAA authorization form. Exclusion Criteria: Subjects requiring hemodialysis or peritoneal dialysis Unstable cardiovascular disease, Uncontrolled hypertension, asthma, diabetes (type I or type II), thyroid disease, or seizure disorder. Myasthenia gravis, or any other neuromuscular disorder. Known infection with Hepatitis B (antigen positive), Hepatitis C (antibody positive), or HIV. Active malignancy; carcinoma in situ of the prostate or the skin (basal cell or squamous cell) are permitted. Presence of functioning transplant organ or blood procedure. Significant change in either over-the-counter or prescription medications or supplements within the two weeks prior to dosing, defined as any new medication or any dosage adjustment that is significant in the judgment of the investigator and the medical monitor. Use of drugs known to cause renal disease such as non-steroidal anti-inflammatory drugs in the two weeks prior to dosing. History of significant hearing loss or a family history of hearing loss, excluding age related (≥ age 65) hearing loss. A prior diagnosis of sensorineural hearing loss or Ménière's disease. Clinically significant illness, including viral syndromes within three weeks of dosing. Current participation in a clinical study of an investigational product. Taken any investigational medication/therapy within 30 days or 5 half-lives, whichever is longer, before dosing of ACHN-490 Injection. Consumed more than 28 units of ethanol per week at any time in the 6 months before dosing (1 unit of ethanol is equivalent to 8 ounces of beer, 4 ounces of wine, or 1 ounce of spirits) or history of alcoholism and/or drug/chemical abuse. Also, consumption of any amount of ethanol within 48 hours of ACHN-490 Injection dosing. Donated more than 500 mL of blood within 60 days prior to signing the informed consent form. Previous participation in this or any other ACHN-490 Injection study. Known hypersensitivity to Aminoglycosides or any component of the ACHN-490 Injection. Any other medical, psychological, or social condition which, in the opinion of the principal investigator (PI) or the medical monitor, would prevent the subject from fully participating in the study, would represent a concern for study compliance or would constitute a safety concern to the subject. An employee of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, or a family member of the employee or investigator.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Director
    Organizational Affiliation
    Achaogen, Inc.
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    30275092
    Citation
    Komirenko AS, Riddle V, Gibbons JA, Van Wart S, Seroogy JD. A Phase 1 Study To Assess the Pharmacokinetics of Intravenous Plazomicin in Adult Subjects with Varying Degrees of Renal Function. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01128-18. doi: 10.1128/AAC.01128-18. Print 2018 Dec.
    Results Reference
    derived

    Learn more about this trial

    PK Study of ACHN-490 Injection in Renally Impaired Subjects

    We'll reach out to this number within 24 hrs